Skip to main content

Table 2 Secondary outcomes—adjusted treatment effects (repeated measures analyses using data from all available timepoints, adjusted for age, sex and CKD category)

From: Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial

 

Treatment effect (bicarbonate–placebo) (95% CI)

p

Physical function and anthropometry

 Six-min walk distance (m)

− 33 (− 62 to − 4)

0.02

 Grip strength (kg)

− 1.5 (− 2.8 to − 0.2)

0.03

 Weight (kg)

0.2 (− 2.9 to 3.4)

0.89

 Mid-arm muscle circumference (cm)

0.0 (− 0.6 to 0.6)

0.99

 Triceps skinfold thickness (mm)

− 1 (− 2 to 1)

0.34

 Mid-thigh circumference (cm)

0.1 (− 0.8 to 1.1)

0.80

Quality of life

 EuroQoL EQ-5D-3L

− 0.04 (− 0.08 to 0.00)

0.06

 EuroQoL EQ-5D visual analogue scale

− 3 (− 7 to 1)

0.09

 KDQOL symptoms

− 1 (− 3 to 2)

0.67

 KDQOL burden of disease

− 3 (− 8 to 2)

0.20

 KDQOL effect of disease

− 2 (− 5 to 1)

0.25

 KDQOL SF-36 physical component summary

− 1 (− 4 to 1)

0.23

 KDQOL SF-36 mental component summary

− 2 (− 4 to 0)

0.03

Renal biochemistry

 Serum bicarbonate (mmol/L)

1.1 (0.6 to 1.6)

< 0.001

 Serum potassium (mmol/L)

0.0 (− 0.1 to 0.1)

0.80

 eGFR (mL/min/1.73 m2)*

0.6 (− 0.8 to 2.0)

0.39

 Serum creatinine (umol/L)*

− 8 (− 28 to 13)

0.46

 Serum cystatin C (mg/L)*

− 0.01 (− 0.17 to 0.14)

0.89

 Log [urinary albumin/creatinine ratio]

0.32 (− 0.05 to 0.70)

0.09

Cardiometabolic risk

 Log [NT-pro-BNP (pg/mL)]

0.13 (− 0.18 to 0.44)

0.42

 Total cholesterol (mmol/L)

0.1 (− 0.2 to 0.3)

0.58

 Systolic blood pressure (mmHg)

0 (− 4 to 3)

0.93

 Diastolic blood pressure (mmHg)

1 (− 1 to 3)

0.16

 HbA1c (mmol/mol)

1 (− 1 to 4)

0.38

Bone and mineral metabolism

 Log [TRACP-5b (IU/L)]

− 0.18 (− 0.43 to 0.08)

0.17

 Log [Bs-ALP (μg/L)]

0.01 (− 0.11 to 0.13)

0.83

 Log [PTH (pmol/L)]

0.03 (− 0.14 to 0.19)

0.75

 Log [25OHD (nmol/L)]

− 0.08 (− 0.23 to 0.06)

0.24

 1,25OHD (pmol/L) (SD)

3 (− 3 to 9)

0.30

 Serum calcium (mmol/L)

0.02 (0.00 to 0.04)

0.11

 Serum phosphate (mmol/L)

0.02 (− 0.03 to 0.06)

0.52

Other

 Haemoglobin (g/L)

− 0.1 (− 0.4 to 0.2)

0.48

 Albumin (g/L)

0 (−1 to 1)

0.67

 Log [TSH (mIU/L)]

0.07 (− 0.10 to 0.24)

0.39

  1. *Repeated measures analyses using data from all available timepoints, adjusted for age and sex only
  2. 1,25OHD 1,25-dihydroxyvitamin D, 25OHD 25-hydroxyvitamin D, NT-pro-BNP N-terminal pro B-type natriuretic peptide, Bs-ALP bone-specific alkaline phosphatase, eGFR estimated glomerular filtration rate, HbA1c glycosylated haemoglobin, KDQOL kidney disease quality of life, PTH parathyroid hormone, SF-36 Short-form 36 questionnaire, TRACP-5b tartrate-resistant acid phosphatase 5b, TSH thyroid-stimulating hormone